The words approved in red capitalized letters

Amphastar receives FDA nod for naloxone hydrochloride

Naloxone hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.
Levy

Amphastar has received the Food and Drug Administration’s blessing for naloxone hydrochloride nasal spray in a dosage strength of 4 mg.

Naloxone hydrochloride nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.

[Read more: Amphastar obtains FDA nod for generic Vasostrict]

Naloxone hydrochloride nasal spray had a market value of $250 million for the 12 months ended Dec. 31, 2022, according to IQVIA.

[Read more: FDA gives Amphastar tentative OK for vasopressin injection]

 

 

X
This ad will auto-close in 10 seconds